Nintedanib in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 32892892.
- Also identified by DOI 10.1016/j.chest.2020.05.557.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (allo-HCT) usually confers poor prognosis and high mortality. Currently, therapeutic options are limited. Here we report an 18-year-old man with acute myeloid leukemia developed BOS after allo-HCT and responded poorly to inhaled corticosteroids and short-acting β-agonist, azithromycin, montelukast, and immunosuppressants. Then he started nintedanib treatment, and the symptoms of nonproductive cough and dyspnea were alleviated gradually. His pulmonary function test revealed increased FEV<sub>1</sub> compared to baseline.
Medical subject headings
- Bronchiolitis Obliterans
- Hematopoietic Stem Cell Transplantation
- Indoles
- Protein Kinase Inhibitors